Frisco, Texas, USA, April 18, 2016 – OxySure Therapeutics, Inc. (OTCQB: OXYS) (“OxySure,” or the “Company”), a global leader and medical device innovator of life-saving, easy-to-use emergency oxygen products with its “oxygen from powder” technology and other innovative emergency medical solutions, today provided the following clarification: "The Company is continuing its previously stated operational strategy, which includes a generation 2 product, and evaluating an outsourcing strategy. At the same time, the Company is pursuing multiple strategic options, including the continuation of its efforts to pursue its previously stated goal of evaluating inorganic growth options."